Physician

Harsha Gadadhar Vardhana, M.D.

According to 2025 Medicare claims, Harsha Vardhana, M.D. (NPI: 1285823658) practices hematology/oncology in the Chattanooga, TN-GA market, with the plurality of this provider's patient population coming from Hamilton, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 37403-2836. Vardhana is affiliated with the Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), participating under the MSSP model.

Vardhana's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 784 traditional Medicare patients, billed 117,197 HCPCS/CPT codes, and received $2,695,502 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 2,065 prescription claims across 311 beneficiaries totaling $4,652,350 in drug costs, led by Revlimid (Lenalidomide). DME data shows 51 claims. Open Payments data shows 17 records totaling $433. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $117,985 to $2,695,502. Similarly, Part D prescription costs have moved sharply higher in recent years, from $798,054 to $4,652,350. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,329 to $1,008.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	344	1,451	$117,985
2016	349	1,633	$142,283
2017	259	1,096	$63,011
2018	219	1,270	$72,747
2019	234	1,297	$68,447
2020	250	16,245	$393,969
2021	394	75,982	$1,521,667
2022	514	69,088	$1,164,681
2023	754	131,117	$2,444,754
2024	784	117,197	$2,695,502

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	145	861	$798,054
2016	147	867	$882,062
2017	115	482	$514,535
2018	106	720	$594,994
2019	117	825	$335,663
2020	136	1,099	$1,168,639
2021	176	964	$1,702,212
2022	237	1,440	$2,364,638
2023	350	2,304	$4,140,895
2024	311	2,065	$4,652,350

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	102	$33,023
2016	N/R	12	$226
2017	N/R	N/R	N/R
2018	N/R	32	$7,199
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	22	$749
2023	N/R	75	$17,973
2024	11	51	$939

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	214	238	$1,036
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	245	477	$83
80053	Blood test, comprehensive group of blood chemicals	303	1,315	$10
36415	Insertion of needle into vein for collection of blood sample	305	1,322	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	304	1,416	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	47	1,264	$853,730
Ibrance	Palbociclib	27	756	$405,600
Calquence	Acalabrutinib Maleate	25	750	$301,437
Lumakras	Sotorasib	13	390	$278,970
Tagrisso	Osimertinib Mesylate	11	660	$196,756

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$450
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	21	$339
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$433	Incyte Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Harsha Gadadhar Vardhana, M.D.?

Tedicare shows public-source Medicare data for Harsha Gadadhar Vardhana, M.D. (NPI 1285823658), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Harsha Gadadhar Vardhana, M.D. have ACO affiliation data?

Harsha Gadadhar Vardhana, M.D. is shown with ACO affiliation data for Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502).

What billing organization is linked to Harsha Gadadhar Vardhana, M.D.?

Harsha Gadadhar Vardhana, M.D. is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Harsha Gadadhar Vardhana, M.D. have Open Payments data?

Harsha Gadadhar Vardhana, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.